Paul Badawi Sells 25,356 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 25,356 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $188,395.08. Following the completion of the sale, the chief executive officer directly owned 5,937,146 shares of the company’s stock, valued at $44,112,994.78. The trade was a 0.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $88,787.60.

Sight Sciences Trading Down 0.4%

Shares of NASDAQ:SGHT opened at $7.44 on Thursday. The company has a 50 day moving average of $7.57 and a 200-day moving average of $5.15. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. The firm has a market cap of $393.35 million, a P/E ratio of -8.27 and a beta of 2.42. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The firm had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. As a group, analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SGHT has been the topic of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Lake Street Capital lifted their price objective on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Piper Sandler set a $9.00 target price on shares of Sight Sciences in a report on Monday. UBS Group increased their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Finally, Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a research report on Monday. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.30.

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight, which can attract buying from institutions and retail investors and support near-term positive sentiment. Read More.
• Neutral Sentiment: Key insiders still hold large stakes (CEO Paul Badawi ~5.9M shares; CTO David Badawi ~1.9M shares), which suggests ongoing long-term alignment despite recent sales and may limit fears of full insider exit. Read More.
• Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 totaling roughly $0.48M in proceeds. The clustered timing and size of the trades — even though each is a small percentage of holdings — can create short-term downward pressure or signal near‑term liquidity needs. Read More.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its holdings in shares of Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after acquiring an additional 3,785 shares during the period. CWM LLC grew its position in Sight Sciences by 70.2% during the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after purchasing an additional 3,137 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares during the period. Bank of Montreal Can purchased a new stake in shares of Sight Sciences in the second quarter valued at $49,000. Finally, R Squared Ltd purchased a new stake in shares of Sight Sciences in the third quarter valued at $64,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.